Predict your next investment

HEALTHCARE | Drug Discovery

See what CB Insights has to offer

Stage

Seed VC | Alive

About Lorem Therapeutics

Lorem Therapeutics is focusing on developing early stage therapeutics in the phase between initial drug discovery and when a treatment begins review by the FDA for status as an Investigational New Drug.

Lorem Therapeutics Headquarter Location

Baltimore, Maryland,

United States

Latest Lorem Therapeutics News

IP Group fills Lorem’s coffers

May 16, 2018

IP Group fills Lorem’s coffers Lorem Therapeutics has become the first Johns Hopkins spinout to secure funding through the institution’s partnership with IP Group. Author: Thierry Heles, editor Lorem Therapeutics, a US-based cancer-focused drug developer, was spun out of Johns Hopkins University yesterday with funding from commercialisation firm IP Group. Financial terms of the deal have not been disclosed. Lorem will also receive support from FastForward, which is operated by the institution’s tech transfer office, Johns Hopkins Technology Ventures, and offers access to office space, services and funding opportunities. Lorem Therapeutics will develop early-stage therapeutics for several cancer indications, with a specific focus on bridging the gap from drug discovery to Investigational New Drug status, which enables companies to ship experimental drugs across US state lines for clinical trials. The spinout is headed by Barbara Slusher, professor of neurology (primary), medicine, psychiatry and neuroscience at Johns Hopkins School of Medicine and director of the institution’s drug discovery program, Johns Hopkins Drug Discovery. Lorem Therapeutics is the first portfolio company at Johns Hopkins University for IP Group, after it signed a partnership agreement with the institution in 2016. Slusher said, “I am delighted to have the support of IP Group, Johns Hopkins Technology Ventures and FastForward as we launch this exciting venture. “IP Group’s commercial expertise and initial funding as well as FastForward’s ongoing support will play a critical role in helping us accelerate and enhance our drug discovery efforts around critical cancer indications.” Michael Burychka, chief executive of IP Group North America, said: “We are excited to announce the first investment from our collaboration with Johns Hopkins University. “IP Group is committed to supporting scientific discovery and is thrilled to work with Dr Slusher. We look forward to building upon our relationship with Johns Hopkins and continuing to invest in novel science being developed at the university.” Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.